Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (→R) |
m |
||
| Line 61: | Line 61: | ||
*[[Brivanib (BMS-582664)]] '''in clinical trials''' | *[[Brivanib (BMS-582664)]] '''in clinical trials''' | ||
*[[Buparlisib (BKM120)]] '''in clinical trials''' | *[[Buparlisib (BKM120)]] '''in clinical trials''' | ||
| − | *[[Busulfan (Myleran)]] | + | *[[Busulfan (Myleran)]] '''FDA approved 2/4/1999''' |
==C== | ==C== | ||
| Line 69: | Line 69: | ||
*[[Calcium phosphate rinse (Caphosol)]] | *[[Calcium phosphate rinse (Caphosol)]] | ||
*[[Capecitabine (Xeloda)]] | *[[Capecitabine (Xeloda)]] | ||
| − | *[[Carboplatin (Paraplatin)]] | + | *[[Carboplatin (Paraplatin)]] '''FDA approved 3/3/1989''' |
*[[Carfilzomib (Kyprolis)]] '''FDA approved 7/20/2012''' | *[[Carfilzomib (Kyprolis)]] '''FDA approved 7/20/2012''' | ||
*[[Carmustine (BiCNU)]] | *[[Carmustine (BiCNU)]] | ||
| Line 81: | Line 81: | ||
*[[Cladribine (Leustatin)]] | *[[Cladribine (Leustatin)]] | ||
*[[Clodronate (Bonefos)]] | *[[Clodronate (Bonefos)]] | ||
| − | *[[Clofarabine (Clolar)]] | + | *[[Clofarabine (Clolar)]] '''FDA approved 12/28/2004''' |
*[[Clopidogrel (Plavix)]] | *[[Clopidogrel (Plavix)]] | ||
*[[Crizotinib (Xalkori)]] | *[[Crizotinib (Xalkori)]] | ||
| Line 153: | Line 153: | ||
*[[Fluorouracil (5-FU)]] | *[[Fluorouracil (5-FU)]] | ||
*[[Floxuridine (FUDR)]] | *[[Floxuridine (FUDR)]] | ||
| − | *[[Fludarabine (Fludara)]] | + | *[[Fludarabine (Fludara)]] '''FDA approved 4/18/1991''' |
*[[Flutamide (Eulexin)]] | *[[Flutamide (Eulexin)]] | ||
*[[Folinic acid (Leucovorin)]] | *[[Folinic acid (Leucovorin)]] | ||
| Line 164: | Line 164: | ||
*[[Ganitumab (AMG 479)]] '''in clinical trials''' | *[[Ganitumab (AMG 479)]] '''in clinical trials''' | ||
*[[Gefitinib (Iressa)]] | *[[Gefitinib (Iressa)]] | ||
| − | *[[Gemcitabine (Gemzar)]] | + | *[[Gemcitabine (Gemzar)]] '''FDA approved 5/15/1996''' |
*[[Gemtuzumab ozogamicin (Mylotarg)]] | *[[Gemtuzumab ozogamicin (Mylotarg)]] | ||
*[[Glucarpidase (Voraxaze)]] '''FDA approved 1/17/2012''' | *[[Glucarpidase (Voraxaze)]] '''FDA approved 1/17/2012''' | ||
| Line 182: | Line 182: | ||
*[[Ifosfamide (Ifex)]] | *[[Ifosfamide (Ifex)]] | ||
*[[IMA901]] '''in clinical trials''' | *[[IMA901]] '''in clinical trials''' | ||
| − | *[[Imatinib (Gleevec)]] | + | *[[Imatinib (Gleevec)]] '''FDA approved 5/10/2001''' |
*[[Inotuzumab ozogamicin (CMC-544)]] '''in clinical trials''' | *[[Inotuzumab ozogamicin (CMC-544)]] '''in clinical trials''' | ||
*[[Ipilimumab (Yervoy)]] | *[[Ipilimumab (Yervoy)]] | ||
| Line 188: | Line 188: | ||
*[[Interferon alfa-2b (Intron-A)]] | *[[Interferon alfa-2b (Intron-A)]] | ||
*[[IPH 2101 (Anti-KIR)]] '''in clinical trials''' | *[[IPH 2101 (Anti-KIR)]] '''in clinical trials''' | ||
| − | *[[Irinotecan (Camptosar)]] | + | *[[Irinotecan (Camptosar)]] '''FDA approved 6/14/1996''' |
*[[Iron dextran (INFeD)]] | *[[Iron dextran (INFeD)]] | ||
*[[Iron sucrose (Venofer)]] | *[[Iron sucrose (Venofer)]] | ||
| Line 247: | Line 247: | ||
*[[Onartuzumab (MetMAb)]] '''in clinical trials''' | *[[Onartuzumab (MetMAb)]] '''in clinical trials''' | ||
*[[Oprelvekin (Neumega)]] | *[[Oprelvekin (Neumega)]] | ||
| − | *[[Oxaliplatin (Eloxatin)]] | + | *[[Oxaliplatin (Eloxatin)]] '''FDA approved 8/9/2002''' |
==P== | ==P== | ||
| Line 318: | Line 318: | ||
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
*[[Tbo-filgrastim (Neutroval)]] '''FDA approved 8/29/2012''' | *[[Tbo-filgrastim (Neutroval)]] '''FDA approved 8/29/2012''' | ||
| − | *[[Temozolomide (Temodar)]] | + | *[[Temozolomide (Temodar)]] '''FDA approved 8/11/1999''' |
*[[Temsirolimus (Torisel)]] | *[[Temsirolimus (Torisel)]] | ||
*[[Teniposide (Vumon)]] | *[[Teniposide (Vumon)]] | ||
| Line 330: | Line 330: | ||
*[[Tivantinib (ARQ 197)]] '''in clinical trials''' | *[[Tivantinib (ARQ 197)]] '''in clinical trials''' | ||
*[[Tivozanib (AV-951)]] '''in clinical trials''' | *[[Tivozanib (AV-951)]] '''in clinical trials''' | ||
| − | *[[Topotecan (Hycamtin)]] | + | *[[Topotecan (Hycamtin)]] '''FDA approved 5/28/1996''' |
*[[Toremifene (Fareston)]] | *[[Toremifene (Fareston)]] | ||
*[[Tosedostat]] '''in clinical trials''' | *[[Tosedostat]] '''in clinical trials''' | ||
| Line 356: | Line 356: | ||
*[[Vincristine liposomal (Marqibo)]] '''FDA approved 8/9/2012''' | *[[Vincristine liposomal (Marqibo)]] '''FDA approved 8/9/2012''' | ||
*[[Vindesine (Eldisine)]] | *[[Vindesine (Eldisine)]] | ||
| − | *[[Vinorelbine (Navelbine)]] | + | *[[Vinorelbine (Navelbine)]] '''FDA approved 12/23/1994''' |
*[[Vismodegib (Erivedge)]] '''FDA approved 1/30/2012''' | *[[Vismodegib (Erivedge)]] '''FDA approved 1/30/2012''' | ||
*[[Volasertib (BI 6727)]] '''in clinical trials''' | *[[Volasertib (BI 6727)]] '''in clinical trials''' | ||
Revision as of 19:30, 5 June 2013
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline (2013)
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline[1]
- ASCO-ONS Standards for Safe Chemotherapy Administration
- Chemotherapy Administration Sequence[2] - with chemotherapy sequencing chart
- The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. PubMed
- FDA drug shortages list
- Steroid conversions
- Vesicant & irritant chemotherapy
A
- Abiraterone (Zytiga)
- Acyclovir (Zovirax)
- Ado-trastuzumab emtansine (Kadcyla) FDA approved 2/22/2013
- Afatinib (BIBW 2992) in clinical trials
- Aldesleukin (Proleukin)
- Alemtuzumab (Campath)
- Alendronate (Fosamax)
- Alisertib (MLN8237) in clinical trials
- All-trans retinoic acid (ATRA)
- Altretamine (Hexalen)
- Amatuximab (MORAb-009) in clinical trials
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Anti-inhibitor coagulant complex (FEIBA NF)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin (ATG)
- Apixaban (Eliquis) FDA approved 12/28/2012
- Apocept (APG101) in clinical trials
- Argatroban
- ARN-509 in clinical trials
- Arsenic trioxide (Trisenox)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Aspirin
- Astuprotimut-R (GSK1572932A) in clinical trials
- Atovaquone (Mepron)
- Axitinib (Inlyta) FDA approved 1/27/2012
- Azacitidine (Vidaza)
B
- Bacillus Calmette-Guerin (BCG)
- Belagenpumatucel-L (Lucanix) in clinical trials
- Bendamustine (Treanda)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Bivalirudin (Angiomax)
- BHQ880 (Anti-DKK1 Antibody) in clinical trials
- Bleomycin (Blenoxane)
- Blinatumomab (MT103) in clinical trials
- Bortezomib (Velcade)
- Bosutinib (Bosulif) FDA approved 9/4/2012
- Brentuximab vedotin (Adcetris)
- Brivanib (BMS-582664) in clinical trials
- Buparlisib (BKM120) in clinical trials
- Busulfan (Myleran) FDA approved 2/4/1999
C
- Cabazitaxel (Jevtana)
- Cabozantinib (Cometriq) FDA approved 11/29/2012
- CAL-101 in clinical trials
- Calcium phosphate rinse (Caphosol)
- Capecitabine (Xeloda)
- Carboplatin (Paraplatin) FDA approved 3/3/1989
- Carfilzomib (Kyprolis) FDA approved 7/20/2012
- Carmustine (BiCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- CAT-3888 (BL22) in clinical trials
- Catumaxomab (Removab) in US clinical trials
- Cetuximab (Erbitux)
- Chlorambucil (Leukeran)
- Cisplatin (Platinol)
- Cixutumumab (IMC-A12) in clinical trials
- Cladribine (Leustatin)
- Clodronate (Bonefos)
- Clofarabine (Clolar) FDA approved 12/28/2004
- Clopidogrel (Plavix)
- Crizotinib (Xalkori)
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine modified (Neoral)
- Cyclosporine non-modified (Sandimmune)
- Cytarabine (Cytosar)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus (CMV) Human Immunoglobulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dabrafenib (Tafinlar) FDA approved 5/29/2013
- Dacarbazine (DTIC)
- Dacomitinib (PF-00299804) in clinical trials
- Dactinomycin (Cosmegen)
- Dalteparin (Fragmin)
- Darbepoetin alfa (Aranesp)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Deferasirox (Exjade)
- Deferiprone (Ferriprox)
- Deferoxamine (Desferal)
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexamethasone (Decadron)
- Dexrazoxane (Zinecard)
- DMUC5754A MMAE in clinical trials
- DN24-02 in clinical trials
- Docetaxel (Taxotere)
- Dovitinib (TKI-258) in clinical trials
- Doxorubicin (Adriamycin)
- Doxorubicin liposomal (Doxil)
- Dutasteride (Avodart)
E
- Eculizumab (Soliris)
- Elotuzumab (HuLuc63) in clinical trials
- Eltrombopag (Promacta)
- Emepepimut-S (Stimuvax) in clinical trials
- Enoxaparin (Lovenox)
- Entinostat in clinical trials
- Enzalutamide (Xtandi) FDA approved 8/31/2012
- Epirubicin (Ellence)
- Epoetin alfa (Procrit)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estramustine (Emcyt)
- Etirinotecan pegol (NKTR-102) in clinical trials
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human and recombinant (antihemophilic factor 8)
- Factor IX, human and recombinant (coagulation factor 9)
- Factor IX complex (Profilnine)
- Factor XIII concentrate, human (Corifact)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Fibrinogen concentrate, human (RiaSTAP)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fludarabine (Fludara) FDA approved 4/18/1991
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Fondaparinux (Arixtra)
- Fulvestrant (Faslodex)
G
- Galeterone (TOK-001) in clinical trials
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar) FDA approved 5/15/1996
- Gemtuzumab ozogamicin (Mylotarg)
- Glucarpidase (Voraxaze) FDA approved 1/17/2012
- Goserelin (Zoladex)
H
- Hematopoetic progenitor cells, cord blood (Hemacord)
- Heparin
- HER2 peptide vaccine (AE37) in clinical trials
- Hydroxyurea (Hydrea)
I
- Ibandronate (Boniva)
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (PCI-32765) in clinical trials
- Idarubicin (Idamycin)
- Ifosfamide (Ifex)
- IMA901 in clinical trials
- Imatinib (Gleevec) FDA approved 5/10/2001
- Inotuzumab ozogamicin (CMC-544) in clinical trials
- Ipilimumab (Yervoy)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- IPH 2101 (Anti-KIR) in clinical trials
- Irinotecan (Camptosar) FDA approved 6/14/1996
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Ixabepilone (Ixempra)
- Ixazomib (MLN9708) in clinical trials
L
- Lanreotide (Somatuline)
- Lapatinib (Tykerb)
- LDK378 in clinical trials
- Lenalidomide (Revlimid)
- Lenvatinib (E7080) in clinical trials
- Lepirudin (Refludan)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Linifanib (ABT-869) in clinical trials
- Lomustine (Ceenu)
M
- Mechlorethamine (Mustargen)
- MEK162 (Arry-162) in clinical trials
- Melphalan (Alkeran)
- Mercaptopurine (Purinethol)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Methylprednisolone (Solumedrol)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- MK-2206 in clinical trials
- Motesanib (AMG 706) in clinical trials
- Moxetumomab pasudotox (HA22) in clinical trials
- MPDL3280A in clinical trials
- Mycophenolate mofetil (CellCept)
N
- Necitumumab (IMC-11F8) in clinical trials
- Nelarabine (Arranon)
- Neratinib (HKI-272) in clinical trials
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- Nintedanib (BIBF 1120) in clinical trials
- Nivolumab (BMS-936558, MDX-1106) in clinical trials
- NovoTTF-100A device
O
- Obinutuzumab (GA101) in clinical trials
- Octreotide (Sandostatin)
- Octreotide LAR (Sandostatin LAR)
- Odanacatib (MK-0822) in clinical trials
- ODM-201 in clinical trials
- Ofatumumab (Arzerra)
- Olaparib (AZD-2281) in clinical trials
- Omacetaxine (Synribo) FDA approved 10/26/2012
- Ombrabulin (AVE8062) in clinical trials
- Onartuzumab (MetMAb) in clinical trials
- Oprelvekin (Neumega)
- Oxaliplatin (Eloxatin) FDA approved 8/9/2002
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Palbociclib (PD-0332991) in clinical trials
- Pamidronate (Aredia)
- Panitumumab (Vectibix)
- Panobinostat (LBH589) in clinical trials
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (PegIntron)
- Pemetrexed (Alimta)
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pertuzumab (Perjeta) FDA approved 6/8/2012
- Phosphomannopentaose sulfate (PI-88) in clinical trials
- Phytonadione (Vitamin K)
- Pixantrone (BBR 2778) in clinical trials
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Pomalidomide (Pomalyst) FDA approved 2/8/2013
- Ponatinib (Iclusig) FDA approved 12/14/2012
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Prasugrel (Effient)
- Prednisone (Sterapred)
- Prednisolone (Millipred)
- Procarbazine (Matulane)
- Protamine sulfate
- Prothrombin Complex Concentrate, Human (Kcentra) FDA approved 4/29/2013
Q
- Quizartinib (AC220) in clinical trials
R
- Radium Ra 223 (Xofigo) FDA approved 5/15/2013
- Raloxifene (Evista)
- Ramucirumab (IMC-1121B) in clinical trials
- Regorafenib (Stivarga) FDA approved 9/27/2012
- Reovirus (Reolysin) in clinical trials
- Retaspimycin (IPI-504) in clinical trials
- Ridaforolimus (AP23573) in clinical trials
- Risedronate (Actonel)
- Rituximab (Rituxan)
- Rivaroxaban (Xarelto)
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ruxolitinib (Jakafi) FDA approved 11/16/2011
S
- S-1 in clinical trials
- Samarium-153 (Quadramet)
- Sapacitabine (CS-682) in clinical trials
- SAR302503 in clinical trials
- SAR3419 in clinical trials
- Sargramostim (Leukine)
- Seliciclib (CYC202) in clinical trials
- Selumetinib (AZD6244) in clinical trials
- Semuloparin (AVE5026) in clinical trials
- Sipuleucel-T (Provenge)
- Sorafenib (Nexavar)
- Streptozocin (Zanosar)
- Sunitinib (Sutent)
T
- Tacrolimus (Prograf)
- Tamoxifen (Nolvadex)
- Tbo-filgrastim (Neutroval) FDA approved 8/29/2012
- Temozolomide (Temodar) FDA approved 8/11/1999
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Tesetaxel (DJ-927) in clinical trials
- TH-302 in clinical trials
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Thioplex)
- Ticagrelor (Brilinta)
- Tigatuzumab (CS-1008) in clinical trials
- Tivantinib (ARQ 197) in clinical trials
- Tivozanib (AV-951) in clinical trials
- Topotecan (Hycamtin) FDA approved 5/28/1996
- Toremifene (Fareston)
- Tosedostat in clinical trials
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trametinib (Mekinist) FDA approved 5/29/2013
- Trastuzumab (Herceptin)
- Trebananib (AMG 386) in clinical trials
- Tretinoin (Vesanoid)
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Triptorelin (Trelstar LA)
U
V
- Valacyclovir (Valtrex)
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Veliparib (ABT-888) in clinical trials
- Veltuzumab (hA20) in clinical trials
- Vemurafenib (Zelboraf)
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo) FDA approved 8/9/2012
- Vindesine (Eldisine)
- Vinorelbine (Navelbine) FDA approved 12/23/1994
- Vismodegib (Erivedge) FDA approved 1/30/2012
- Volasertib (BI 6727) in clinical trials
- Von Willebrand Factor and factor VIII complex, human
- Vorinostat (Zolinza)
W
X
- XL647 (KD019) in clinical trials
Z
- Ziv-aflibercept (Zaltrap) FDA approved 8/3/2012
- Zoledronic acid (Zometa)
References
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article